Craig-Hallum Adjusts MiMedx Group, Inc. (MDXG) Outlook on CMS Coverage Guidance

Core Viewpoint - MiMedx Group, Inc. (NASDAQ:MDXG) is recognized as one of the best biotech stocks under $20, despite recent adjustments to price targets by analysts due to changes in CMS guidance affecting wound care volumes [1][2][3]. Group 1: Analyst Adjustments - Craig-Hallum analyst Chase Knickerbocker lowered the price target on MDXG to $10 from $13 while maintaining a Buy rating, citing expected provider confusion and pressure on wound care volumes in Q1 2026 [2]. - Northland Securities also reduced its price target on MDXG to $10 from $12, maintaining an Outperform rating, and adjusted FY2026 and FY2027 forecasts due to near-term uncertainties related to CMS's flat-rate coverage for skin substitutes [3]. Group 2: Company Overview - MiMedx Group, Inc. is a U.S. biomedical company that specializes in developing and distributing advanced placental tissue allografts for applications in wound care, surgery, and burns, utilizing proprietary processing methods to aid in treating chronic and hard-to-heal wounds [4].